Publication: Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
Issued Date
2019-02-01
Resource Type
ISSN
23125098
2312508X
2312508X
Other identifier(s)
2-s2.0-85065992221
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
ERS Monograph. Vol.5, No.1 (2019)
Suggested Citation
Pouline M. Van Oort, Lieuwe D. Bos, Pedro Póvoa, Paula Ramirez, Antoni Torres, Antonio Artigas, Marcus J. Schultz, Ignacio Martin-Loeches Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia. ERS Monograph. Vol.5, No.1 (2019). doi:10.1183/23120541.00212-2018 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51932
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
Other Contributor(s)
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias
NOVA Medical School - Faculdade de Ciências Médicas, Universidade Nova de Lisboa
Hospital Universitari i Politècnic La Fe
Hospital Clinic Barcelona
Universitat Autònoma de Barcelona
Mahidol University
Hospital São Francisco Xavier
Amsterdam UMC - University of Amsterdam
Sagrado-Corazón Hospital
St James’s University Hospital
NOVA Medical School - Faculdade de Ciências Médicas, Universidade Nova de Lisboa
Hospital Universitari i Politècnic La Fe
Hospital Clinic Barcelona
Universitat Autònoma de Barcelona
Mahidol University
Hospital São Francisco Xavier
Amsterdam UMC - University of Amsterdam
Sagrado-Corazón Hospital
St James’s University Hospital
Abstract
© ERS 2019. Introduction: Diagnosing ventilator-associated pneumonia (VAP) remains challenging. Soluble urokinase plasminogen activator receptor (suPAR) has prognostic value in critically ill patients with systemic infection. We hypothesised that plasma suPAR levels accurately predict development of VAP. Methods: This observational, multicentre, prospective cohort study compared patients at risk for VAP with a control group. Plasma and tracheal aspirate samples were collected. Plasma suPAR levels were measured on the day of diagnosis and 3 days before diagnosis. Results: The study included 24 VAP patients and 19 control patients. The suPAR concentration measured 3 days before diagnosis was significantly increased in VAP patients versus matched samples of control patients (area under the receiver operating characteristic curve (AUC) 0.68, 95% CI 0.52-1.00; p=0.04). Similar results were found on the day of diagnosis (AUC 0.77, 95% CI 0.6-0.93; p=0.01). Plasma suPAR was significantly higher in deceased patients (AUC 0.79, 95% CI 0.57-1.00; p<0.001). Combining suPAR with the Clinical Pulmonary Infection Score, C-reactive protein and/or procalcitonin led to a significantly increased discriminative accuracy for predicting VAP and an increased specificity. Conclusions: suPAR can be used to diagnose VAP with a fair diagnostic accuracy and has a moderate prognostic accuracy to be used in critically ill intensive care unit patients. Its performance improves when added to other clinically available biomarkers (C-reactive protein and procalcitonin) or scoring systems (Clinical Pulmonary Infection Score and Sepsis-related Organ Failure Assessment).